Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

The KRASG12C Inhibitor, MRTX849, Provides Insight Toward Therapeutic Susceptibility of KRAS Mutant Cancers in Mouse Models and Patients.

Hallin J, Engstrom LD, Hargis L, Calinisan A, Aranda R, Briere DM, Sudhakar N, Bowcut V, Baer BR, Ballard JA, Burkard MR, Fell JB, Fischer JP, Vigers GP, Xue JY, Gatto S, Fernandez-Banet J, Pavlicek A, Velastegui K, Chao RC, Barton J, Pierobon M, Baldelli E, Patricoin EF, Cassidy DP, Marx MA, Rybkin II, Johnson ML, Ou SI, Lito P, Papadopoulos KP, Janne PA, Olson P, Christensen JG.

Cancer Discov. 2019 Oct 28. pii: CD-19-1167. doi: 10.1158/2159-8290.CD-19-1167. [Epub ahead of print]

PMID:
31658955
2.

Turnover of ribosome-associated transcripts from de novo ORFs produces gene-like characteristics available for de novo gene emergence in wild yeast populations.

Durand É, Gagnon-Arsenault I, Hallin J, Hatin I, Dubé AK, Nielly-Thibault L, Namy O, Landry CR.

Genome Res. 2019 Jun;29(6):932-943. doi: 10.1101/gr.239822.118. Epub 2019 May 31.

3.

Discovery of Tetrahydropyridopyrimidines as Irreversible Covalent Inhibitors of KRAS-G12C with In Vivo Activity.

Fell JB, Fischer JP, Baer BR, Ballard J, Blake JF, Bouhana K, Brandhuber BJ, Briere DM, Burgess LE, Burkard MR, Chiang H, Chicarelli MJ, Davidson K, Gaudino JJ, Hallin J, Hanson L, Hee K, Hicken EJ, Hinklin RJ, Marx MA, Mejia MJ, Olson P, Savechenkov P, Sudhakar N, Tang TP, Vigers GP, Zecca H, Christensen JG.

ACS Med Chem Lett. 2018 Nov 7;9(12):1230-1234. doi: 10.1021/acsmedchemlett.8b00382. eCollection 2018 Dec 13.

PMID:
30613331
4.

The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy.

Briere D, Sudhakar N, Woods DM, Hallin J, Engstrom LD, Aranda R, Chiang H, Sodré AL, Olson P, Weber JS, Christensen JG.

Cancer Immunol Immunother. 2018 Mar;67(3):381-392. doi: 10.1007/s00262-017-2091-y. Epub 2017 Nov 9.

PMID:
29124315
5.

Clonal Heterogeneity Influences the Fate of New Adaptive Mutations.

Vázquez-García I, Salinas F, Li J, Fischer A, Barré B, Hallin J, Bergström A, Alonso-Perez E, Warringer J, Mustonen V, Liti G.

Cell Rep. 2017 Oct 17;21(3):732-744. doi: 10.1016/j.celrep.2017.09.046.

6.

Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models.

Engstrom LD, Aranda R, Lee M, Tovar EA, Essenburg CJ, Madaj Z, Chiang H, Briere D, Hallin J, Lopez-Casas PP, Baños N, Menendez C, Hidalgo M, Tassell V, Chao R, Chudova DI, Lanman RB, Olson P, Bazhenova L, Patel SP, Graveel C, Nishino M, Shapiro GI, Peled N, Awad MM, Jänne PA, Christensen JG.

Clin Cancer Res. 2017 Nov 1;23(21):6661-6672. doi: 10.1158/1078-0432.CCR-17-1192. Epub 2017 Aug 1.

7.

Contrasting evolutionary genome dynamics between domesticated and wild yeasts.

Yue JX, Li J, Aigrain L, Hallin J, Persson K, Oliver K, Bergström A, Coupland P, Warringer J, Lagomarsino MC, Fischer G, Durbin R, Liti G.

Nat Genet. 2017 Jun;49(6):913-924. doi: 10.1038/ng.3847. Epub 2017 Apr 17.

8.

Powerful decomposition of complex traits in a diploid model.

Hallin J, Märtens K, Young AI, Zackrisson M, Salinas F, Parts L, Warringer J, Liti G.

Nat Commun. 2016 Nov 2;7:13311. doi: 10.1038/ncomms13311.

9.

Scan-o-matic: High-Resolution Microbial Phenomics at a Massive Scale.

Zackrisson M, Hallin J, Ottosson LG, Dahl P, Fernandez-Parada E, Ländström E, Fernandez-Ricaud L, Kaferle P, Skyman A, Stenberg S, Omholt S, Petrovič U, Warringer J, Blomberg A.

G3 (Bethesda). 2016 Sep 8;6(9):3003-14. doi: 10.1534/g3.116.032342.

10.

Predicting quantitative traits from genome and phenome with near perfect accuracy.

Märtens K, Hallin J, Warringer J, Liti G, Parts L.

Nat Commun. 2016 May 10;7:11512. doi: 10.1038/ncomms11512.

11.

Mitotic Checkpoint Kinase Mps1 Has a Role in Normal Physiology which Impacts Clinical Utility.

Martinez R, Blasina A, Hallin JF, Hu W, Rymer I, Fan J, Hoffman RL, Murphy S, Marx M, Yanochko G, Trajkovic D, Dinh D, Timofeevski S, Zhu Z, Sun P, Lappin PB, Murray BW.

PLoS One. 2015 Sep 23;10(9):e0138616. doi: 10.1371/journal.pone.0138616. eCollection 2015.

12.

Chemogenetic evaluation of the mitotic kinesin CENP-E reveals a critical role in triple-negative breast cancer.

Kung PP, Martinez R, Zhu Z, Zager M, Blasina A, Rymer I, Hallin J, Xu M, Carroll C, Chionis J, Wells P, Kozminski K, Fan J, Guicherit O, Huang B, Cui M, Liu C, Huang Z, Sistla A, Yang J, Murray BW.

Mol Cancer Ther. 2014 Aug;13(8):2104-15. doi: 10.1158/1535-7163.MCT-14-0083-T. Epub 2014 Jun 13.

13.

PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity.

Yuan J, Mehta PP, Yin MJ, Sun S, Zou A, Chen J, Rafidi K, Feng Z, Nickel J, Engebretsen J, Hallin J, Blasina A, Zhang E, Nguyen L, Sun M, Vogt PK, McHarg A, Cheng H, Christensen JG, Kan JL, Bagrodia S.

Mol Cancer Ther. 2011 Nov;10(11):2189-99. doi: 10.1158/1535-7163.MCT-11-0185. Epub 2011 Jul 12.

14.

PF-00477736 mediates checkpoint kinase 1 signaling pathway and potentiates docetaxel-induced efficacy in xenografts.

Zhang C, Yan Z, Painter CL, Zhang Q, Chen E, Arango ME, Kuszpit K, Zasadny K, Hallin M, Hallin J, Wong A, Buckman D, Sun G, Qiu M, Anderes K, Christensen JG.

Clin Cancer Res. 2009 Jul 15;15(14):4630-40. doi: 10.1158/1078-0432.CCR-08-3272. Epub 2009 Jul 7.

15.

Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1.

Blasina A, Hallin J, Chen E, Arango ME, Kraynov E, Register J, Grant S, Ninkovic S, Chen P, Nichols T, O'Connor P, Anderes K.

Mol Cancer Ther. 2008 Aug;7(8):2394-404. doi: 10.1158/1535-7163.MCT-07-2391.

16.

Automatic fitting procedures for EPR spectra of disordered systems: matrix diagonalization and perturbation methods applied to fluorocarbon radicals.

Lund A, Andersson P, Eriksson J, Hallin J, Johansson T, Jonsson R, Löfgren H, Paulin C, Tell A.

Spectrochim Acta A Mol Biomol Spectrosc. 2008 May;69(5):1294-300. Epub 2007 Oct 6.

PMID:
18006375
17.

Explicit gauge-invariant quantization of the Schwinger model on a circle in the functional Schrödinger representation.

Hallin J, Liljenberg P.

Phys Rev D Part Fields. 1996 Jul 15;54(2):1723-1735. No abstract available.

PMID:
10020848
18.

Fermionic and bosonic pair creation in an external electric field at finite temperature using the functional Schrödinger representation.

Hallin J, Liljenberg P.

Phys Rev D Part Fields. 1995 Jul 15;52(2):1150-1164. No abstract available.

PMID:
10019331

Supplemental Content

Loading ...
Support Center